|
Sub-category:
Lower Gastrointestinal Cancer
Category:
Gastrointestinal Cancer
Meeting:
2003 ASCO Annual Meeting
Session Type and Session Title:
This abstract will not be presented at the 2003 ASCO Annual Meeting but has been published in conjunction with the meeting.
Abstract No:
1228
Citation:
Proc Am Soc Clin Oncol 22: 2003 (abstr 1228)
Author(s):
Y. Ogata, T. Sasatomi, Y. Araki, N. Ishibashi, M. Kanazawa, K. Matono, S. Torigoe, K. Shirouzu, for the Kurume Colorectal Oncology Group; Kurume University, Kurume-city, Japan
Abstract:
[Purpose] This study was conducted to investigate the efficacy and safety of concomitant therapy with low-dose irinotecan hydrochloride (CPT-11) + doxifluridine (5’- DFUR: an intermediate metabolite of capecitabine) in patients with MCRC. [Patients and Methods] Twenty-five patients, who were definitely diagnosed with MCRC by histological examination of lesions, were given concomitant therapy with CPT-11 40 mg/m2/w (i.v.) + 5’- DFUR 800 mg/body (p.o.) from day 3 to day 7 in the outpatient clinic. [Results] The efficacy and safety of this combination was evaluable for all 25 patients enrolled in the present study between August 2000 and November 2002. Primary tumor sites were colon (13 patients) and rectal (12 patients). Median age was 60 years (39 – 77). The major metastatic sites were located in the liver (60%) and lungs (56%). Thirteen patients (52%) had previously received 5-FU/LV and / or hepatic arterial infusion for metastatic disease. Efficacy of this treatment was: PR in 7 patients, NC in 13 patients, and PD in 5 patients, indicating the response rate of 28% (95% CI: 12.1 - 49.4%). PFS was 5.3 months and MST was 18.4 months. Adverse drug reactions were observed in 21 of the 25 patients (84%), including malaise (56%), nausea (48%), alopecia (24%), leukopenia (20%), and diarrhea (16%). Diarrhea was serious (Grade 3) in 1 patient, but other adverse reactions were mild (Grades 1/2). [Conclusion] Excellent therapeutic effects can be expected in the treatment of MCRC by concomitant therapy with low-dose CPT-11 + the oral fluoropyrimidine 5’-DFUR, drugs which are well tolerated by these patients. The concomitant therapy, which can be given in the outpatient clinic, is expected to be very convenient. A phase Ⅱ study is scheduled for the near future.
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by Y. Ogata:
Presentations by Y. Ogata:
Educational Book Manuscripts by Y. Ogata:
|
